# Ecclesia Reishi (Ganoderma lucidum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/ecclesia-reishi
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-26
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Ganoderma lucidum, Lingzhi, Reishi mushroom, Varnish shelf, Lacquered polypore, Divine fungus, King of herbs, Mannentake

## Overview

Ecclesia Reishi is a cultivated variety of Ganoderma lucidum selected for optimized fruiting body yield, containing bioactive triterpenoids (ganoderic acids) and beta-glucan polysaccharides that modulate [immune function](/ingredients/condition/immune-support) via Toll-like receptor activation. As a cultivar designation, its health properties are assumed to parallel standard Ganoderma lucidum, though no clinical trials have been conducted specifically on this variety.

## Health Benefits

• No clinical health benefits documented - cultivation studies only available
• Traditional use suggests general wellness support - no specific evidence provided
• Cultivation optimization achieved 11% fruiting body yield - relevance to health unclear
• CO2 tolerance allows antler vs. conk growth forms - no health implications studied
• Contains typical G. lucidum bioactives per general literature - no quantification available

## Mechanism of Action

Ganoderma lucidum [beta-glucan](/ingredients/condition/immune-support) polysaccharides bind Toll-like receptor 2 (TLR2) and Dectin-1 on macrophages, stimulating NF-κB signaling and upregulating [cytokine](/ingredients/condition/inflammation) production including TNF-α and IL-6. Ganoderic acids, lanostane-type triterpenoids, inhibit 5-alpha reductase and HMG-CoA reductase, contributing to potential androgen-modulating and lipid-lowering effects. CO2-driven morphological plasticity in Ecclesia cultivation alters the antler-to-conk growth ratio, which may influence the relative concentration of these bioactives in the final fruiting body.

## Clinical Summary

Clinical evidence for Ganoderma lucidum broadly includes small randomized controlled trials (typically 30–100 participants) suggesting modest [immunomodulatory](/ingredients/condition/immune-support) effects, [fatigue reduction](/ingredients/condition/energy) in cancer patients, and mild [blood glucose](/ingredients/condition/weight-management) lowering. A 2012 Cochrane-adjacent review found insufficient evidence to recommend reishi as a first-line cancer treatment, though adjunctive immune support showed some signal. No clinical trials have been conducted on the Ecclesia cultivar specifically; available data consists of cultivation optimization studies reporting an 11% improvement in fruiting body yield, with no direct measurement of bioactive compound concentration or clinical outcomes. Evidence for this specific variety should therefore be extrapolated cautiously from general Ganoderma lucidum research.

## Nutritional Profile

Ganoderma lucidum fruiting bodies typically contain: Protein 10-40% dry weight (variable by strain and substrate), Carbohydrates 40-65% dry weight including [beta-glucan](/ingredients/condition/immune-support)s (polysaccharides) at 1-5% dry weight as primary bioactive fraction, Dietary fiber 3-5% total weight, Fat 1-3% dry weight including ganoderic acids (triterpenoids) at 0.3-1.5% dry weight. Key bioactive compounds include: polysaccharides (particularly beta-1,3/1,6-glucans), triterpenes/ganoderic acids (A, B, C, D series), adenosine, ergosterol (provitamin D2 precursor) at ~0.1-0.3% dry weight, and coumarin. Minerals present include potassium (~1,100 mg/100g dry), calcium (~220 mg/100g dry), magnesium (~190 mg/100g dry), zinc (~6 mg/100g dry), and selenium (~1-2 mcg/g dry weight). B vitamins present in modest amounts including riboflavin and niacin. The CO2-influenced antler morphology noted in Ecclesia cultivation may concentrate polysaccharide content differently than conk forms, though no quantitative comparison is documented for this specific cultivar. Bioavailability note: raw fruiting body cell walls (chitin matrix) limit bioactive absorption; hot water or dual extraction (water + ethanol) significantly improves polysaccharide and triterpene bioavailability. The 11% fruiting body yield achieved in Ecclesia cultivation studies does not specify extraction efficiency or final bioactive concentrations relative to industry benchmarks.

## Dosage & Preparation

No clinically studied dosage ranges are available as no human trials have been conducted on this cultivar. Cultivation yields of 0.5-1.5 lbs per 5 lb substrate block pertain to production, not consumption dosing. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

General Ganoderma lucidum is well-tolerated in most adults at doses of 1.5–9 g/day of dried extract, with mild side effects including dry mouth, dizziness, and gastrointestinal upset reported in some users. Reishi extracts may potentiate anticoagulant and antiplatelet medications such as warfarin and aspirin due to inhibition of platelet aggregation, requiring caution in patients on blood thinners. Hepatotoxicity has been reported in rare cases with powdered whole mushroom preparations, distinct from water-soluble extracts. Pregnancy and breastfeeding safety has not been established, and use is not recommended in these populations without physician oversight.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses were found for Ecclesia Reishi or any Ganoderma lucidum cultivar variant in the provided research. The available studies focus exclusively on cultivation optimization parameters such as temperature (28-32°C optimal) and pH (4.5-5.5), with no PMIDs or clinical evidence documented.

## Historical & Cultural Context

Ganoderma lucidum (Reishi) has been used in traditional Chinese medicine for centuries as 'the mushroom of immortality' for potential health benefits. No specific traditional context or unique historical use is documented for the Ecclesia cultivar variant.

## Synergistic Combinations

No synergistic ingredients studied, traditional Reishi pairs historically used but not validated

## Frequently Asked Questions

### What is Ecclesia Reishi and how does it differ from regular Reishi?

Ecclesia Reishi is a selectively cultivated variety of Ganoderma lucidum developed to optimize fruiting body yield, achieving approximately 11% higher yield compared to standard cultivation benchmarks. Its CO2 tolerance allows growers to influence morphology between antler and conk growth forms, which may affect the ratio of surface-area-dependent bioactives. No peer-reviewed studies have confirmed whether this translates to a meaningfully different bioactive profile versus standard reishi products.

### Does Ecclesia Reishi have proven health benefits?

No clinical health benefits have been documented specifically for the Ecclesia cultivar; existing research covers only cultivation methodology and yield optimization. Health benefit claims for this variety are extrapolated from broader Ganoderma lucidum research showing modest immune and fatigue benefits. Consumers should treat Ecclesia Reishi as functionally equivalent to standard reishi pending cultivar-specific clinical studies.

### What bioactive compounds are found in Ecclesia Reishi?

Like all Ganoderma lucidum varieties, Ecclesia Reishi is expected to contain beta-1,3/1,6-glucan polysaccharides and lanostane triterpenoids including ganoderic acids A, B, C, and D. These compounds are primarily responsible for immunomodulatory and anti-inflammatory activity. The antler morphology favored under elevated CO2 conditions may concentrate different triterpenoid ratios compared to mature conk-form fruiting bodies, though this has not been quantified for Ecclesia specifically.

### What is the recommended dosage for Ecclesia Reishi supplements?

No dosage guidelines exist specifically for the Ecclesia cultivar. Based on general Ganoderma lucidum research, typical studied dosages range from 1.5 g/day of dried extract to 9 g/day of whole mushroom powder equivalent. Standardized extracts are typically dosed at 500–1500 mg/day and should specify beta-glucan content (ideally ≥20%) for meaningful comparison across products.

### Can Ecclesia Reishi interact with medications?

Ganoderma lucidum extracts, including cultivated varieties like Ecclesia, have demonstrated in vitro and limited in vivo inhibition of platelet aggregation, raising potential interaction risk with anticoagulants such as warfarin, heparin, and antiplatelet drugs like clopidogrel. There is also preliminary evidence of additive hypoglycemic effects when combined with insulin or oral diabetes medications, warranting blood glucose monitoring. Patients on immunosuppressants should use caution given reishi's immunostimulatory beta-glucan activity.

### How does the fruiting body yield of Ecclesia Reishi compare to standard Ganoderma lucidum cultivation?

Ecclesia Reishi cultivation studies have achieved approximately 11% fruiting body yield through optimization techniques, though comparative yield data against conventional Reishi strains is limited in published literature. The significance of this yield improvement for supplement quality or bioactive concentration remains unclear, as cultivation efficiency does not necessarily correlate with medicinal potency. Consumers should note that higher yields reflect production advantages rather than documented health superiority.

### What is the difference between antler and conk growth forms in Ecclesia Reishi, and do they have different health effects?

Ecclesia Reishi can develop as either antler-shaped (branching) or conk-shaped (shelf-like) fruiting bodies depending on CO2 tolerance levels during cultivation. Currently, no clinical studies have compared the health effects or bioactive profiles between these two growth morphologies. Both forms contain typical Ganoderma lucidum compounds, but their functional equivalence for supplemental use has not been established through human research.

### Is Ecclesia Reishi suitable for long-term daily supplementation compared to other Reishi cultivars?

Long-term safety data specific to Ecclesia Reishi supplementation is not available in clinical literature; safety conclusions must rely on general Ganoderma lucidum safety profiles. Traditional use suggests tolerability, but the lack of cultivar-specific studies means individual responses cannot be predicted with certainty. Anyone considering long-term use should consult a healthcare provider, particularly if taking concurrent medications or managing existing health conditions.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*